Financials

News Ideas Discussions Technicals Forecast Seasonals

ALCJ fundamentals

Overview Statements Statistics Dividends Earnings Revenue

Key facts

—

—

—

—

—

—

—

—

About

Crossject SA manufactures and markets needle free injection system. It develops and produces generic drugs such as methotrexate, epinephrin, and sumatriptan. The company distributes its products under the Zeneo brand. Crossject was founded by Patrick Alexandre and Xavière Castano on August 8, 2001 and is headquartered in Dijon, France.

Valuation

Fundamental metrics to determine fair value of the stock

Summary

No data available

There's currently no market capitalization, revenue or net income data to show.

Valuation ratios

Growth and Profitability

Company’s recent performance and margins

Dividends

Dividend yield, history and sustainability

No dividends

ALCJ has never paid dividends and has no current plans to do so.

Financial health

Financial position and solvency of the company